ACTU
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Actuate Therapeutics, Inc. Common stock (ACTU) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at D+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | D (1.4) | D (1.2) | F (0.5) | C+ (2.6) | D+ (1.6) |
| 2026-11-10 | C+ (2.5) | C- (2.0) | D (1.2) | F (0.5) | C+ (2.6) | D+ (1.8) |
| 2026-11-03 | C+ (2.5) | C- (1.9) | D (1.2) | F (0.5) | C+ (2.7) | D+ (1.8) |
| 2026-10-27 | C+ (2.5) | C- (1.9) | D+ (1.5) | D- (0.7) | C+ (2.6) | C- (1.9) |
| 2026-10-20 | C+ (2.5) | C- (1.9) | D+ (1.5) | D- (0.7) | C+ (2.6) | C- (1.9) |